{"id":5628,"date":"2025-12-12T09:58:19","date_gmt":"2025-12-12T09:58:19","guid":{"rendered":"https:\/\/regenerated.health\/low-libido-women\/"},"modified":"2026-07-28T10:02:41","modified_gmt":"2026-07-28T10:02:41","slug":"low-libido-women","status":"publish","type":"post","link":"https:\/\/regenerated.com\/blog\/low-libido-women\/","title":{"rendered":"Low Libido in Women: Hormonal and Non-Hormonal Approaches"},"content":{"rendered":"\n<div class=\"at-a-glance\">\n<h2>At a Glance<\/h2>\n<ul>\n<li>Low sexual desire affects up to 40% of women at some point, making it the most common female sexual complaint<\/li>\n<li>Causes are almost always multifactorial: hormonal shifts, relationship dynamics, stress, medications, and medical conditions all play a role<\/li>\n<li>Testosterone therapy in low doses shows consistent benefits for postmenopausal women but remains off-label in the US<\/li>\n<li>FDA-approved medications (flibanserin and bremelanotide) work for some women, but the average benefit is modest<\/li>\n<li>Psychological approaches, especially mindfulness-based therapy, have evidence comparable to or better than pharmacological options<\/li>\n<\/ul>\n<\/div>\n\n<h2>How Common Is Low Libido in Women?<\/h2>\n\n<p>Low sexual desire is the most frequently reported sexual concern among women worldwide. Epidemiological studies estimate that 26-43% of women experience low desire at some point in their lives, with about 8-12% meeting criteria for clinically significant distress about it [1].<\/p>\n\n<p>That distinction matters. Many women have lower desire than they once did or lower desire than their partner, but it does not bother them. Low desire becomes a clinical issue only when it causes personal distress. The medical framework should follow the woman&#8217;s experience, not an arbitrary standard of how much desire is &#8220;normal.&#8221;<\/p>\n\n<p>Prevalence increases somewhat with age, but low desire is not limited to menopause. Women in their 20s and 30s present with this concern regularly, often driven by different factors than those affecting older women.<\/p>\n\n<h2>HSDD: The Diagnosis and Its Limitations<\/h2>\n\n<p>Hypoactive Sexual Desire Disorder (HSDD) was the diagnostic label used for decades. It was defined as persistently deficient or absent sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty [2].<\/p>\n\n<p>The DSM-5 merged HSDD with Female Sexual Arousal Disorder into Female Sexual Interest\/Arousal Disorder (FSIAD), reflecting the reality that desire and arousal are deeply intertwined in women. In practice, most clinicians still use HSDD because the FDA-approved medications were studied under that framework. The terminology matters less than the clinical reality: a woman is distressed by persistent low desire not explained by another condition, relationship problems alone, or medication effects.<\/p>\n\n<h2>Hormonal Factors Behind Low Desire<\/h2>\n\n<h3>Testosterone<\/h3>\n\n<p>Testosterone is not just a &#8220;male hormone.&#8221; Women produce testosterone in the ovaries and adrenal glands, and it plays a significant role in sexual desire, arousal, and orgasmic function. Women&#8217;s testosterone levels peak in their early 20s and decline gradually, dropping roughly 50% by menopause [3].<\/p>\n\n<p>After surgical menopause (removal of both ovaries), testosterone levels fall abruptly and dramatically. This often correlates with a sharp drop in desire that estrogen therapy alone does not fully restore.<\/p>\n\n<p>However, there is no well-established testosterone threshold below which desire predictably disappears. Some women function well sexually with relatively low testosterone. Others are symptomatic at levels that look &#8220;normal&#8221; on a lab test. This makes clinical management more nuanced than simply checking a number.<\/p>\n\n<h3>Estrogen<\/h3>\n\n<p>Estrogen&#8217;s role in desire is indirect but important. During perimenopause and menopause, declining estrogen causes vaginal dryness, thinning of vaginal tissue, and pain with intercourse. When sex hurts, avoidance behavior naturally follows, and the brain starts associating sexual situations with discomfort rather than pleasure [4].<\/p>\n\n<p>This creates a cycle: low estrogen causes vaginal atrophy, which causes pain, which causes avoidance, which gets labeled as &#8220;low desire.&#8221; In many cases, treating the vaginal atrophy reveals that desire was intact all along. The body was simply protecting itself from a painful experience.<\/p>\n\n<h3>Thyroid Dysfunction<\/h3>\n\n<p>Both hypothyroidism and hyperthyroidism affect sexual function. Hypothyroidism is particularly associated with decreased desire, reduced arousal, and difficulty with orgasm. A 2018 study found that 46% of women with hypothyroidism reported sexual dysfunction compared to 20% of euthyroid controls [5]. Thyroid function should be checked in any evaluation of persistent low desire, especially if accompanied by fatigue, weight changes, or mood shifts.<\/p>\n\n<h3>Cortisol and the Stress Response<\/h3>\n\n<p>Chronic stress elevates cortisol, which suppresses the hypothalamic-pituitary-gonadal (HPG) axis. This reduces production of both testosterone and estrogen. But the effect goes beyond hormones. When the nervous system is in a persistent threat-detection state, the brain deprioritizes sexual interest. From an evolutionary standpoint, this makes sense. Your body diverts resources away from reproduction when survival feels uncertain.<\/p>\n\n<h2>Non-Hormonal Factors<\/h2>\n\n<h3>Medications<\/h3>\n\n<p>SSRIs and SNRIs are among the most common causes of medication-induced low desire. Between 40-65% of people on these medications experience sexual side effects, including reduced desire, delayed orgasm, or anorgasmia [6]. Other medications that can suppress libido include hormonal contraceptives (some formulations more than others), antihypertensives, antihistamines, and opioids.<\/p>\n\n<p>If low desire started around the time a new medication began, that connection needs to be explored with your prescriber. Switching to bupropion, mirtazapine, or other antidepressants with lower sexual side effect profiles can make a significant difference.<\/p>\n\n<h3>Relationship Dynamics<\/h3>\n\n<p>Desire does not exist in a vacuum. Research consistently shows that relationship satisfaction is one of the strongest predictors of sexual desire in women. Unresolved conflict, feeling undervalued, unequal division of household labor, lack of emotional intimacy, and partner sexual dysfunction all suppress desire [7].<\/p>\n\n<p>This is not about pathologizing the woman. If desire is low because a relationship is not functioning well, the treatment is the relationship, not a medication. Couples therapy or sex therapy is the appropriate intervention.<\/p>\n\n<h3>Body Image and Self-Consciousness<\/h3>\n\n<p>Cognitive distraction during sexual activity, often called &#8220;spectatoring,&#8221; is a well-documented inhibitor of arousal and desire. Women preoccupied with how their body looks during sex have significantly lower satisfaction and desire. This affects women across all body types.<\/p>\n\n<h3>History of Trauma<\/h3>\n\n<p>Sexual trauma and negative early sexual experiences can profoundly affect desire, often operating outside conscious awareness. Trauma-informed therapy with a qualified provider is essential in these cases.<\/p>\n\n<h2>Testosterone Therapy for Women<\/h2>\n\n<p>Testosterone supplementation for women with low desire has the strongest pharmacological evidence of any treatment for this condition. A 2019 systematic review and meta-analysis of 36 randomized controlled trials found that transdermal testosterone consistently increased satisfying sexual events, desire, and arousal in postmenopausal women [3].<\/p>\n\n<p>The effect sizes were moderate but clinically meaningful. Women on testosterone reported approximately one additional satisfying sexual event per month compared to placebo, along with improvements in desire, arousal, and orgasm scores.<\/p>\n\n<h3>Dosing and Delivery<\/h3>\n\n<p>The evidence supports testosterone doses that raise levels into the premenopausal physiological range (roughly 1-3.5 nmol\/L total testosterone). This typically means transdermal application: a testosterone cream or gel applied daily at roughly one-tenth the male dose [8].<\/p>\n\n<p>Oral testosterone and injections are not recommended for women due to unpredictable blood levels and greater risk of androgenic side effects (acne, hair growth, voice deepening).<\/p>\n\n<h3>The Regulatory Situation<\/h3>\n\n<p>Here is the frustrating reality: no testosterone product is FDA-approved for women in the United States. The Australian product Androfeme (1% testosterone cream) is approved specifically for female HSDD, but it is not available in the US. American women who receive testosterone therapy get it off-label, typically from compounding pharmacies.<\/p>\n\n<p>Major medical societies, including the International Society for the Study of Women&#8217;s Sexual Health (ISSWSH) and the Endocrine Society, have published position statements supporting testosterone use in postmenopausal women with HSDD, with appropriate monitoring [8]. The gap between evidence and regulatory status is a policy issue, not a science one.<\/p>\n\n<h3>Monitoring<\/h3>\n\n<p>Women on testosterone therapy should have blood levels checked at 3-6 weeks and then every 6 months. Providers should also monitor lipid panels and watch for androgenic side effects. At physiological female doses, virilization is rare but possible if dosing is not carefully managed.<\/p>\n\n<h2>FDA-Approved Medications<\/h2>\n\n<h3>Flibanserin (Addyi)<\/h3>\n\n<p>Flibanserin is a serotonin receptor agonist\/antagonist taken daily at bedtime. It works on central neurotransmitter pathways rather than hormones, reducing serotonin (which inhibits desire) while increasing dopamine and norepinephrine (which promote it) [9].<\/p>\n\n<p>Efficacy: Clinical trials showed an average increase of 0.5-1 additional satisfying sexual events per month compared to placebo. Desire scores improved modestly. About one-third of women experience a clinically meaningful response.<\/p>\n\n<p>The downsides are real: flibanserin requires daily dosing (unlike an as-needed medication), takes 4-8 weeks to reach full effect, cannot be combined with alcohol (risk of severe hypotension and syncope), and causes dizziness, drowsiness, and nausea in a significant minority. Many women try it and discontinue within 6 months.<\/p>\n\n<h3>Bremelanotide (Vyleesi)<\/h3>\n\n<p>Bremelanotide is a melanocortin receptor agonist given as a subcutaneous injection 45 minutes before anticipated sexual activity. It works through a different mechanism than flibanserin, activating melanocortin pathways involved in sexual arousal [9].<\/p>\n\n<p>Efficacy is similar to flibanserin: modest but statistically significant improvements in desire and reductions in distress. The main advantages are that it is used on-demand rather than daily and has no alcohol interaction.<\/p>\n\n<p>The main side effect is nausea, which affects about 40% of women with the first dose and tends to decrease with subsequent use. It can also cause transient increases in blood pressure, so it is not recommended for women with uncontrolled hypertension or cardiovascular disease.<\/p>\n\n<p>Neither of these medications is a &#8220;female Viagra.&#8221; They produce modest average benefits, and the women who respond well tend to have clearly identifiable HSDD without significant relationship, mood, or hormonal confounders. Setting realistic expectations is important.<\/p>\n\n<h2>Treating Vaginal Atrophy and Pain<\/h2>\n\n<p>When vaginal dryness and pain are contributing to avoidance and declining desire, treating the genital tissue directly can be remarkably effective.<\/p>\n\n<ul>\n<li><strong>Local estrogen:<\/strong> Vaginal estrogen creams, tablets, or rings deliver low-dose estrogen directly to vaginal tissue. Systemic absorption is minimal. These treatments restore vaginal elasticity, lubrication, and pH, and are safe even in women for whom systemic estrogen therapy is contraindicated [4].<\/li>\n<li><strong>Intravaginal DHEA (prasterone):<\/strong> FDA-approved for painful intercourse due to menopause. DHEA is converted locally to both estrogen and testosterone in vaginal tissue. Some women prefer it because it provides both hormonal effects without systemic estrogen.<\/li>\n<li><strong>Ospemifene:<\/strong> An oral SERM (selective estrogen receptor modulator) approved for painful intercourse. It provides estrogenic effects on vaginal tissue without being an estrogen. An option for women who prefer an oral treatment.<\/li>\n<\/ul>\n\n<p>For many women, resolving pain through these treatments restores the desire that was suppressed by a conditioned avoidance response. This is often the single most impactful intervention in perimenopausal and postmenopausal women presenting with &#8220;low desire.&#8221;<\/p>\n\n<h2>Psychological Approaches<\/h2>\n\n<h3>Mindfulness-Based Therapy<\/h3>\n\n<p>Mindfulness-based cognitive therapy adapted for sexual concerns has surprisingly strong evidence. Lori Brotto&#8217;s research group has published multiple studies showing that mindfulness training improves sexual desire, arousal, and satisfaction in women with HSDD. A 2022 randomized trial found that a group-based mindfulness intervention was as effective as a psychoeducation\/cognitive behavioral intervention [10].<\/p>\n\n<p>The mechanism is straightforward: mindfulness reduces the cognitive distraction and self-judgment that suppress arousal. By training attention to stay with physical sensations rather than drifting to performance anxiety, body image concerns, or to-do lists, women experience more of the arousal signals that drive desire.<\/p>\n\n<h3>Sensate Focus<\/h3>\n\n<p>Originally developed by Masters and Johnson, sensate focus is a structured series of touching exercises designed to reduce performance pressure and rebuild physical intimacy. Couples progress through stages from non-genital touching to genital touching to intercourse, with clear rules that take &#8220;performance&#8221; off the table.<\/p>\n\n<p>Sensate focus works well when anxiety, pressure, or disconnection is driving the desire problem. It is often part of sex therapy with a certified sex therapist (look for AASECT certification).<\/p>\n\n<h3>Cognitive Behavioral Therapy (CBT)<\/h3>\n\n<p>CBT for low desire addresses the thought patterns that interfere with sexual motivation: catastrophic thinking about sexual &#8220;failure,&#8221; rigid beliefs about how desire should work, and avoidance patterns. It is particularly useful for women whose desire issue has become entangled with anxiety or depression.<\/p>\n\n<h2>The Biopsychosocial Model: Putting It Together<\/h2>\n\n<p>Female sexual desire operates on the intersection of biology, psychology, and social context. This is not a platitude. It is a clinical reality that determines treatment success. A woman with low testosterone, relationship stress, and SSRI-induced anorgasmia will not respond to any single intervention.<\/p>\n\n<p>Effective evaluation means assessing all three domains:<\/p>\n\n<ul>\n<li><strong>Biological:<\/strong> Hormone levels (testosterone, estrogen, thyroid, prolactin), medication review, pain assessment, chronic illness screening<\/li>\n<li><strong>Psychological:<\/strong> Mood disorders, body image, trauma history, cognitive patterns around sex, stress levels<\/li>\n<li><strong>Social\/Relational:<\/strong> Relationship satisfaction, partner health and function, life stage demands, cultural attitudes toward sexuality<\/li>\n<\/ul>\n\n<p>Treatment should address what is actually driving the problem, not default to a medication because it is the simplest intervention. Sometimes the right answer is testosterone. Sometimes it is changing an SSRI. Sometimes it is couples therapy. Often it is a combination.<\/p>\n\n<h2>When to Seek Evaluation<\/h2>\n\n<p>Consider a clinical evaluation if:<\/p>\n\n<ul>\n<li>Low desire has persisted for 6 months or longer and causes personal distress<\/li>\n<li>Desire change coincided with a new medication, surgery, or medical diagnosis<\/li>\n<li>Pain during sex is contributing to avoidance<\/li>\n<li>You suspect a hormonal shift (perimenopause, postpartum, thyroid symptoms)<\/li>\n<li>Low desire is accompanied by fatigue, mood changes, or other systemic symptoms<\/li>\n<\/ul>\n\n<p>The right starting point depends on the likely driver. A gynecologist or endocrinologist for hormonal evaluation. A sex therapist or psychologist for psychological factors. Ideally, a sexual medicine specialist who can evaluate all domains. These specialists are becoming more accessible through academic medical centers and through the ISSWSH provider directory.<\/p>\n\n<h2>Related Reading<\/h2>\n<ul>\n<li><a href=\"\/blog\/category\/sexual-wellness-optimization\/\">Sexual Wellness: The Evidence-Based Guide<\/a> (Pillar)<\/li>\n<li><a href=\"\/blog\/perimenopause-symptoms\">Perimenopause Symptoms: What to Expect and When<\/a><\/li>\n<li><a href=\"\/blog\/ed-treatment-comparison\">ED Treatments Compared: PDE5 Inhibitors vs P-Shot vs Shockwave<\/a><\/li>\n<li><a href=\"\/blog\/trt-side-effects\">TRT Side Effects: What to Expect and How to Manage Them<\/a><\/li>\n<li><a href=\"\/blog\/ed-and-heart-health\">ED and Heart Health: What the Vascular Connection Means<\/a><\/li>\n<\/ul>\n\n<h2>References<\/h2>\n<ol>\n<li>Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. <em>Obstet Gynecol<\/em>. 2008;112(5):970-978. doi:10.1097\/AOG.0b013e3181898cdb<\/li>\n<li>Clayton AH, Goldstein I, Kim NN, et al. The International Society for the Study of Women&#8217;s Sexual Health process of care for management of hypoactive sexual desire disorder in women. <em>Mayo Clin Proc<\/em>. 2018;93(4):467-487. doi:10.1016\/j.mayocp.2017.11.002<\/li>\n<li>Islam RM, Bell RJ, Green S, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. <em>Lancet Diabetes Endocrinol<\/em>. 2019;7(10):754-766. doi:10.1016\/S2213-8587(19)30189-5<\/li>\n<li>Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women&#8217;s Sexual Health and the North American Menopause Society. <em>Menopause<\/em>. 2014;21(10):1063-1068. doi:10.1097\/GME.0000000000000329<\/li>\n<li>Atis G, Dalkilinc A, Altuntas Y, et al. Sexual dysfunction in women with clinical hypothyroidism and subclinical hypothyroidism. <em>J Sex Med<\/em>. 2010;7(7):2583-2590. doi:10.1111\/j.1743-6109.2010.01815.x<\/li>\n<li>Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. <em>J Clin Psychopharmacol<\/em>. 2009;29(3):259-266. doi:10.1097\/JCP.0b013e3181a5233f<\/li>\n<li>Mark KP, Murray SH. Gender differences in desire discrepancy as a predictor of sexual and relationship satisfaction in a college sample of heterosexual romantic relationships. <em>J Sex Marital Ther<\/em>. 2012;38(2):198-215. doi:10.1080\/0092623X.2011.606877<\/li>\n<li>Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. <em>J Clin Endocrinol Metab<\/em>. 2019;104(10):4660-4666. doi:10.1210\/jc.2019-01603<\/li>\n<li>Jaspers L, Feys F, Bramer WM, et al. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. <em>JAMA Intern Med<\/em>. 2016;176(4):453-462. doi:10.1001\/jamainternmed.2015.8565<\/li>\n<li>Brotto LA, Bergeron S, Engel B, et al. A comparison of mindfulness-based cognitive therapy vs cognitive behavioral sex therapy for the treatment of provoked vestibulodynia in a hospital clinic setting. <em>J Sex Med<\/em>. 2022;19(4):621-634. doi:10.1016\/j.jsxm.2022.01.527<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Up to 40% of women experience low sexual desire at some point. Here is what drives it, what the research says about hormonal and non-hormonal treatments, and how to figure out which approach fits your situation.<\/p>\n","protected":false},"author":1,"featured_media":6213,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","_regenerated_references":"","footnotes":""},"categories":[1000],"tags":[],"class_list":["post-5628","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sexual-wellness-optimization"],"_links":{"self":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/comments?post=5628"}],"version-history":[{"count":2,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5628\/revisions"}],"predecessor-version":[{"id":6901,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5628\/revisions\/6901"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/media\/6213"}],"wp:attachment":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/media?parent=5628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/categories?post=5628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/tags?post=5628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}